Strong Week for Supernus Pharmaceuticals (NASDAQ:SUPN) Shareholders Doesn't Alleviate Pain of Five-year Loss

The main aim of stock picking is to find the market-beating stocks. But every investor is virtually certain to have both over-performing and under-performing stocks. So we wouldn't blame long term S

Simply Wall StJun 25 07:38 ET

Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

ROCKVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

GlobeNewswireMay 30 16:25 ET

TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $43

TD Cowen analyst Stacy Ku maintains $Supernus Pharmaceuticals(SUPN.US)$ with a buy rating, and maintains the target price at $43.According to TipRanks data, the analyst has a success rate of 23.8% and

moomoo NewsMay 24 08:33 ET

Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $41

Piper Sandler analyst David Amsellem maintains $Supernus Pharmaceuticals(SUPN.US)$ with a buy rating, and maintains the target price at $41.According to TipRanks data, the analyst has a success rate o

moomoo NewsMay 24 07:33 ET

Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Maintains Target Price $38

Stifel analyst Annabel Samimy maintains $Supernus Pharmaceuticals(SUPN.US)$ with a hold rating, and maintains the target price at $38.According to TipRanks data, the analyst has a success rate of 45.5

moomoo NewsMay 24 07:33 ET

Piper Sandler Sticks to Its Buy Rating for Supernus Pharmaceuticals (SUPN)

TipRanksMay 24 06:46 ET